Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Re-evaluating PARP1 inhibitor in cancer

Nature Biotechnology volume 29, pages 1078–1079 (2011)Cite this article

Subjects

To the Editor:

A News story in the May issue by Malini Guha discusses recent clinical setbacks of poly(ADP-ribose) polymerase 1 (PARP1) inhibitors for the treatment of certain cancers1. Agreeing with the article's conclusion that it is too early to discount the effectiveness of PARP1 inhibitors in cancer treatments, I outline below three principal problems regarding our understanding of PARP1 function and the role of PARP1 inhibitors in limiting tumor growth that could hamper their progress in the clinic.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Model explaining the differences in PARP1 inhibitor effectiveness between inhibitor-sensitive and inhibitor-insensitive cancer cells.

References

  1. Guha, M. Nat. Biotechnol. 29, 373–374 (2011).

    Article  CAS  Google Scholar 

  2. D'Amours, D., Desnoyers, S., D'Silva, I. & Poirier, G.G. Biochem. J. 342, 249–268 (1999).

    Article  CAS  Google Scholar 

  3. Menisser-de Murcia, J., Mark, M., Wendling, O., Wynshaw-Boris, A. & de Murcia, G. Mol. Cell. Biol. 21, 1828–1832 (2001).

    Article  CAS  Google Scholar 

  4. Gottipati, P. et al. Cancer Res. 70, 5389–5398 (2010).

    Article  CAS  Google Scholar 

  5. Mendoza-Alvarez, H. & Alvarez-Gonzalez, R. J. Biol. Chem. 268, 22575–22580 (1993).

    CAS  PubMed  Google Scholar 

  6. Krishnakumar, R. et al. Science 319, 819–821 (2008).

    Article  CAS  Google Scholar 

  7. Tulin, A., Stewart, D. & Spradling, A.C. Genes Dev. 16, 2108–2119 (2002).

    Article  CAS  Google Scholar 

  8. Beneke, S. et al. Nucleic Acids Res. 36, 6309–6317 (2008).

    Article  CAS  Google Scholar 

  9. Salvati, E. et al. Oncogene 29, 6280–6293 (2010).

    Article  CAS  Google Scholar 

  10. Aubin, R.J. et al. EMBO J. 2, 1685–1693 (1983).

    Article  CAS  Google Scholar 

  11. Tulin, A. & Spradling, A. Science 299, 560–562 (2003).

    Article  CAS  Google Scholar 

  12. Kim, M.Y., Mauro, S., Gevry, N., Lis, J.T. & Kraus, W.L. Cell 119, 803–814 (2004).

    Article  CAS  Google Scholar 

  13. Oliver, F.J. et al. EMBO J. 18, 4446–4454 (1999).

    Article  CAS  Google Scholar 

  14. Dajee, M. et al. Nature 421, 639–643 (2003).

    Article  CAS  Google Scholar 

  15. Petesch, S.J. & Lis, J.T. Cell 134, 74–84 (2008).

    Article  CAS  Google Scholar 

  16. Leu, J.I., Pimkina, J., Frank, A., Murphy, M.E. & George, D.L. Mol. Cell 36, 15–27 (2009).

    Article  CAS  Google Scholar 

  17. Bryant, H.E. et al. Nature 434, 913–917 (2005).

    Article  CAS  Google Scholar 

  18. Tulin, A., Naumova, N.M., Menon, A.K. & Spradling, A.C. Genetics 172, 363–371 (2006).

    Article  CAS  Google Scholar 

  19. Kotova, E., Jarnik, M. & Tulin, A.V. PLoS Genet. 5, e1000387 (2009).

    Article  Google Scholar 

  20. Pinnola, A.D., Naumova, N., Shah, M. & Tulin, A.V. J. Biol. Chem. 282, 32511–32519 (2007).

    Article  CAS  Google Scholar 

  21. Kotova, E. et al. Proc. Natl. Acad. Sci. USA 108, 6205–6210 (2011).

    Article  CAS  Google Scholar 

  22. Kotova, E., Pinnola, A.D. & Tulin, A.V. Methods Mol. Biol. 780, 491–516 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

    Alexei Tulin

Authors
  1. Alexei Tulin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexei Tulin.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tulin, A. Re-evaluating PARP1 inhibitor in cancer. Nat Biotechnol 29, 1078–1079 (2011). https://doi.org/10.1038/nbt.2058

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2058

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer